Advertisement
UK markets closed
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • CRUDE OIL

    83.31
    +0.62 (+0.75%)
     
  • GOLD FUTURES

    2,400.20
    +11.80 (+0.49%)
     
  • DOW

    37,864.54
    +111.23 (+0.29%)
     
  • Bitcoin GBP

    51,139.02
    +2,710.32 (+5.60%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,715.78
    +32.40 (+0.21%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

Moving Average Crossover Alert: ABB (ABB)

Zacks.com featured highlights include: Twitter, Lockheed Martin, Intercontinental Exchange, CBRE and Keurig Dr Pepper

ABB Ltd ABB could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ABB broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

This has already started to take place, as the stock has moved lower by 5.2% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ABB stock.

If that wasn’t enough, ABB isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.

Consider that in the last 30 days, 1 estimate have been reduced, while none has moved higher. Add this in to a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.

ADVERTISEMENT

That is why we currently have a Zacks Rank #4 (Sell) on this stock and are looking for it to underperform in the weeks ahead. So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for ABB. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ABB Ltd (ABB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.